Stay updated on Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page.
Latest updates to the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedFooter now displays Revision: v3.3.3 and the HHS Vulnerability Disclosure and Revision: v3.3.2 entries were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRevision history shows the addition of v3.3.2 and the removal of v3.2.0, reflecting administrative version-control updates to the record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check48 days agoChange DetectedRemoved the government funding status notice from the page. This is an administrative update that does not affect trial details or history.SummaryDifference0.5%
- Check63 days agoChange DetectedNew version 31 (2025-05-12) adds a Recruitment Status update to the study record. This update affects the current status shown in the record's history.SummaryDifference0.1%
- Check91 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference10%
- Check99 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.3%
Stay in the know with updates to Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page.